WEBULL
WebtradeDownload

Royalty Pharma (RPRX) Stock Looks Above Fair Value Despite Royalty Portfolio Focus

Simply Wall St · 3d ago

Royalty Pharma has ridden a strong multi year upswing, and that kind of run naturally raises the question of whether the current share price still lines up with what its earnings can support. For a stock built around collecting royalties on blockbuster drugs rather than developing them, the key issue now is how much of that business model is already reflected in today's valuation.

  • Over the past 3 years the stock has returned 165.9%, which puts real pressure on the earnings profile to justify the higher expectations now embedded in the price.
  • Recent coverage has highlighted that Royalty Pharma earns its income from royalties on a broad portfolio of approved and late stage drugs, which can support more stable earnings than a single product biotech and directly affects how investors weigh its P/E against the Fair Ratio benchmark.
  • Your read on Royalty Pharma is one view; the desks covering it have another. See what analysts think Royalty Pharma's shares could be worth.

The issue now is whether Royalty Pharma's recent share price level is adequately supported by the earnings it generates today and what investors expect those earnings to look like over time.

If you are considering whether Royalty Pharma's earnings still justify this share price, it may be useful to ask the same question across 42 high quality undervalued stocks.

Is Royalty Pharma Getting Expensive on Earnings?

For a royalties collector like Royalty Pharma, earnings tend to matter more than revenue when you think about what you are being asked to pay for each dollar of profit. On a P/E of 44.9x, the stock trades well above the broader Pharmaceuticals sector, which is on an average of 16.1x, but only slightly below the 48.5x level across closer peers.

The Fair Ratio model, which adjusts for Royalty Pharma's growth profile, margins, scale and risk, points to a lower P/E than where the shares trade today, so on this framework the stock screens as overvalued. Because the group collects royalties on dozens of approved and late stage drugs, including several blockbuster products, the current premium multiple reflects investors placing a high value on that diversified stream. Because recent coverage has highlighted the breadth of this royalty portfolio and its income potential, the P/E still implies a rich price tag compared with what the tailored benchmark suggests. Explore the numbers behind Royalty Pharma's P/E valuation.

NasdaqGS:RPRX P/E Ratio as at Nov 2026
NasdaqGS:RPRX P/E Ratio as at Nov 2026

The Royalty Pharma Narrative: What Would Justify Today's Price?

Narratives pick up where the P/E puzzle leaves off for Royalty Pharma, by explaining which paths for growth, profitability and earnings would need to occur for the stock to appear meaningfully cheaper or more expensive than it does today. These narratives are available on Simply Wall St's Community page. Rather than relying on a single multiple or model output, each narrative outlines the assumptions behind its estimate of fair value so you can compare those expectations with actual results as they are reported.

Community views on Royalty Pharma are split between those who see more upside in the model and those who think expectations already look full.

Bull case: roughly fairly valued

"Royalty Pharma has built an R&D co-funding franchise with large pharmaceutical companies, including recent US$500m commitments with Teva and Johnson & Johnson..."

Discover why this Narrative puts Royalty Pharma at roughly fairly valued.

Bear case: roughly fairly valued

"Royalty Pharma’s reliance on capital intensive royalty deals is becoming more apparent, since long term revenue growth over the last five years was only 2.1% CAGR..."

Explore why this Narrative puts Royalty Pharma at roughly fairly valued.

Royalty Pharma’s valuation still hinges on one unanswered question

Everything so far has focused on what Royalty Pharma looks like today, yet analyst models sketch out where earnings might be a few years from now and give you a different lens on this price. Explore where analysts expect Royalty Pharma to be in a few years.